<DOC>
	<DOCNO>NCT02667704</DOCNO>
	<brief_summary>The trial design investigate whether , extent , multiple dos bosentan may influence plasma level nintedanib administer single dose .</brief_summary>
	<brief_title>Influence Bosentan Pharmacokinetics Nintedanib</brief_title>
	<detailed_description />
	<mesh_term>Nintedanib</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>Inclusion criterion : Healthy male subject accord investigator assessment , base complete medical history include physical examination , vital sign ( BP , PR ) , 12lead ECG , clinical laboratory test Age 18 55 year ( incl . ) BMI 18.5 29.9 kg/m2 ( incl . ) Signed date write informed consent prior admission study accordance GCP local legislation Males willing use medically acceptable method contraception study ( start treatment end trial examination ) . Acceptable method contraception use male volunteer include sexual abstinence , vasectomy perform least 1 year prior dosing , barrier contraception ( condom ) . Subjects , vasectomise sexually abstinent ensure additional acceptable method contraception use female partner IUD ( intrauterine device ) , surgical sterilisation ( include hysterectomy ) , hormonal contraception ( e.g . implant , injectables , combine oral vaginal contraceptive ) start least 2 month prior first nintedanib administration , barrier method ( e.g . diaphragm spermicide ) . Exclusion criterion : Any find medical examination ( include BP , PR ECG ) deviate normal judge clinically relevant investigator Repeated measurement systolic blood pressure outside range 90 140 mmHg , diastolic blood pressure outside range 50 90 mmHg , pulse rate outside range 45 90 bpm Any laboratory value outside reference range investigator considers clinical relevance Any evidence concomitant disease judge clinically relevant investigator Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Cholecystectomy and/or surgery gastrointestinal tract could interfere pharmacokinetics trial medication ( except appendectomy simple hernia repair ) Diseases central nervous system ( include limit kind seizure stroke ) , relevant neurological psychiatric disorder History relevant orthostatic hypotension , faint spell , blackout Chronic relevant acute infection History relevant allergy hypersensitivity ( include allergy trial medication excipients ) Intake drug long halflife ( 24 h ) within 30 day less 10 halflives respective drug prior administration trial medication Within 10 day prior administration trial medication , use drug might reasonably influence result trial Participation another trial investigational drug administer within 60 day prior plan administration trial medication Smoker ( 10 cigarette 3 cigar 3 pipe per day ) Inability refrain smoke specify trial day Alcohol abuse ( consumption 30 g per day male ) Drug abuse positive drug screen Blood donation 100 mL within 30 day prior administration trial medication intend donation trial Intention perform excessive physical activity within one week prior administration trial medication trial Inability comply dietary regimen trial site Subject assess unsuitable inclusion investigator , instance , consider able understand comply study requirement , condition would allow safe participation study Laboratory parameter ALT , AST GGT outside reference range Intake drug inhibit efflux bile salt ( e.g . rifampicin , glibenclamide , cyclosporine ) within 30 day prior administration trial medication</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>